RUSSELL HIRSCH, MD, PHD
Prospect Venture Partners – Managing Director
Russell Hirsch - Prospect Ventures Managing Director
Russell is a co-founder and Managing Director of Prospect Venture Partners II and III, two life science funds with more than $1 billion of committed capital dedicated to investing in and supporting breakthrough biomedical companies. Russell has led numerous successful investments at Prospect in biotechnology and medical devices including Aveo Pharmaceuticals, Baxano, Hansen Medical, NinePoint Medical, Portola Pharmaceuticals, SentreHEART, and Visiogen among others.
Previously, Russell served as a General Partner at the Mayfield Fund where he actively participated in building the firm’s biotechnology and medical device venture capital practice and led a series of successful investments including to help incubate Millennium Pharmaceuticals and Intuitive Surgical Devices.
Prior to Mayfield, Russell was an accomplished research scientist. After earning his MD and PhD from University of California, San Francisco (UCSF), Russell continued at UCSF and conducted important research related to hepatitis B viral replication among other areas. His research on reverse transcription and packaging functions of polymerase gene products was published in the prestigious journal Nature.
University of California, San Francisco – MD, PhD
University of Chicago – BA
Russell Hirsch online:
Prospect Ventures Russell Hirsch on Crunchbase
Prospect Ventures Russell Hirsch on Bloomberg
Prospect Ventures Russell Hirsch on Stanford’s Graduate School of Business
Russell Hirsch in the news:
Portola Board Appointment of Prospect Ventures Russell Hirsch
Prospect Venture Partners Closes $500 Million Fund
Russell Hirsch's past events:
Prospect Ventures Russell Hirsch at The New York Academy of Sciences